Ben Taylor Biography and Net Worth

Ben Taylor comes to Recursion after over 4 years as the CFO of Exscientia. Ben has more than two decades of experience in healthcare investment banking and executive roles, including 15 years at Goldman Sachs and Barclays in the U.S., Asia and Europe. During this period, Ben focused on financing, strategic and cross-border transactions in the biopharmaceutical industry. Ben served as President and CFO for Tyme Technologies, a NASDAQ-listed oncology focused biotechnology company, where he oversaw the company’s advancement from Phase 1 to Phase 3. Prior to joining Exscientia, Ben was interim CFO at Aetion, a healthtech company using real world data analytics to optimise biopharma clinical development and commercialisation.

What is Ben R. Taylor's net worth?: The estimated net worth of Ben R. Taylor is at least $3.97 million as of February 18th, 2026. Taylor owns 1,195,349 shares of Recursion Pharmaceuticals stock worth more than $3,968,559 as of March 18th. This net worth approximation does not reflect any other investments that Taylor may own. Learn More about Ben R. Taylor's net worth.
How do I contact Ben R. Taylor?: The corporate mailing address for Taylor and other Recursion Pharmaceuticals executives is 41S RIO GRANDE STREET, SALT LAKE CITY UT, 84101. Recursion Pharmaceuticals can also be reached via phone at 385-269-0203 and via email at [email protected]. Learn More on Ben R. Taylor's contact information.
Has Ben R. Taylor been buying or selling shares of Recursion Pharmaceuticals?: Within the last three months, Ben R. Taylor has sold $41,352.08 in Recursion Pharmaceuticals stock. Most recently, Ben R. Taylor sold 13,426 shares of the business's stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $3.08, for a transaction totalling $41,352.08. Following the completion of the sale, the chief financial officer now directly owns 1,195,349 shares of the company's stock, valued at $3,681,674.92. Learn More on Ben R. Taylor's trading history.
Who are Recursion Pharmaceuticals' active insiders?: Recursion Pharmaceuticals' insider roster includes Blake Borgeson (Director), Terry-Ann Burrell (Director), Zavain Dar (Director), Christopher Gibson (CEO), Najat Khan (Insider), Tina Larson (COO), Dean Li (Director), Tina Marriott (President & COO), Michael Secora (CFO), Ben Taylor (CFO), and Shafique Virani (Chief Corporate Development Officer). Learn More on Recursion Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Recursion Pharmaceuticals?: In the last year, insiders at the sold shares 8 times. They sold a total of 884,109 shares worth more than $3,820,775.03. The most recent insider tranaction occured on March, 9th when CEO Najat Khan sold 28,298 shares worth more than $94,798.30. Insiders at Recursion Pharmaceuticals own 8.4% of the company. Learn More about insider trades at Recursion Pharmaceuticals.
Information on this page was last updated on 3/9/2026.

Ben R. Taylor Insider Trading History at Recursion Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/18/2026	Sell	13,426	$3.08	$41,352.08	1,195,349
12/29/2025	Sell	21,383	$4.18	$89,380.94	761,550

Ben R. Taylor Buying and Selling Activity at Recursion Pharmaceuticals

Recursion Pharmaceuticals Company Overview

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Today's Range

Now: $3.32

$3.30

$3.50

50 Day Range

MA: $3.95

$3.29

$4.96

2 Week Range

Now: $3.32

$2.98

$7.18

Volume

14,353,744 shs

Average Volume

17,223,722 shs

Market Capitalization

$1.75 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.97